Company Overview - Tongling Jeya Biotechnology Co., Ltd. was established in 1999, specializing in the research, production, and sales of wet wipes, with over 20 years of industry experience [3]. - The company was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on December 3, 2021, and is currently advancing its fundraising projects [3]. Financial Performance - For the first three quarters of 2025, the company reported a revenue of CNY 565 million and a net profit of CNY 6.79 million [3]. - The primary reason for the revenue growth in 2025 is attributed to an increase in orders from foreign clients [3]. Business Strategy and Operations - The company is accelerating its global business layout, with expectations that foreign sales will account for over 50% of total business this year [3]. - The current capacity utilization rate is over 80%, and new capacity can be added within three to six months [3]. Future Plans - The U.S. factory is currently under construction, with plans to introduce automated production lines and optimize management processes to control costs, aiming for production in 2026 [3]. - Key future growth drivers include deepening cooperation with existing international brand clients and the new market opportunities presented by the U.S. factory [4]. Risk Factors - Investment risks associated with the U.S. factory include potential delays in production, customer approval processes, and cultural differences affecting production efficiency [3]. Competitive Advantages - The company has developed significant core competitive advantages in technology research and development, production processes, quality control, customer resources, and product variety through years of focused development in the wet wipes market [4].

Core Insights - The company plans to establish an advanced integrated packaging system (OPS) production facility in Saudi Arabia, highlighting its global strategy to strengthen its position in the polyolefin industry and ensure local production of high-quality OPS products for Saudi customers [1] Group 1: Investment and Production Plans - The new state-of-the-art factory is expected to be completed by 2028 and will be wholly owned by the company, producing a range of SonGNOX OPS high-performance additive mixtures to support efficient polyolefin resin production [1] - The facility aims to enhance local production capacity and improve supply chain flexibility, thereby better serving the rapidly growing polyolefin market in the Middle East [1] Group 2: Strategic Commitment - The CEO emphasized that this investment is a significant step in expanding the company's global OPS business footprint and reflects its commitment to the key polyolefin market and Saudi Arabia's Vision 2030 [1] - The new factory is expected to open new possibilities for growth and future expansion, enabling the company to provide reliable and effective services to customers in the Middle East and beyond [1] Group 3: Regional Impact - The regional manager highlighted that the strategically located new factory will complement the existing production network and enhance the company's ability to effectively serve customers in Saudi Arabia [1] - This move not only demonstrates the company's commitment to the important region but also reflects its determination to lead in operational excellence and sustainable development [1]

Company Overview - Tongling Jieya Biotechnology Co., Ltd. was established in 1999, specializing in the research, production, and sales of wet wipes, with over 20 years of industry experience [2] - The company went public on the Shenzhen Stock Exchange's Growth Enterprise Market on December 3, 2021, and is steadily advancing its fundraising projects [2] Financial Performance - In Q1 2025, the company reported a revenue of 124 million yuan and a net profit of 1,006.27 million yuan [2] Business Expansion - The company aims to increase its overseas orders to over 50% in 2025, focusing on core customer global business expansion [3] - The U.S. wet wipes factory is currently under construction and is expected to commence production next year [3] Cost Management - The U.S. factory will enhance operational efficiency and optimize cost structure through automation and improved management processes [3] Investment Risks - Key investment risks for the U.S. factory include uncertainties in facility renovation and approval processes, customer audit outcomes, potential production delays, and cultural differences affecting efficiency [3] Current Business Status - Since Q2 2025, the wet wipes business has seen stable orders from existing clients and has taken on new business from key clients in Europe and Canada [3] - The cosmetics business primarily focuses on OEM for international brands, with ongoing efforts to expand domestic client orders, albeit at a smaller scale [3] - The collagen business, established in partnership with Jiangsu Chuangjian, is currently undergoing strategic adjustments due to rapid market changes [3] Brand Development - The company's self-branded initiatives, previously funded, have not met expectations, leading to a significant reduction in investment while continuing to pursue brand development [3] Future Business Drivers - Future growth will rely on expanding existing brand client business, including product categories and sales regions, as well as leveraging the U.S. factory [4] Compliance and Governance - The investor communication event adhered to the Shenzhen Stock Exchange's regulations, ensuring no significant undisclosed information was leaked [4]